Modulation of inflammatory mediators is a clinical reality: TNF-α antagonists have been used for years in ankylosing spondylitis and rheumatoid arthritis with good results, including slowing of the spinal manifestations of these diseases. Here, TNF is linked to rheumatoid arthritis.